Related Experiment Videos
In vivo antitumor activity of TT-232 a novel somatostatin analog
1National Institute of Oncology, Department of Experimental Pharmacology, Budapest, Hungary.
Abstract:
The somatostatin analog TT-232 containing a 5 residue ring, was previously shown to inhibit the proliferation of a large number of cancer cell lines in vitro and reduce the size of tumors in animal models in vivo. Its action is accompanied by inhibition of tyrosine kinases and is characterized by the induction of programmed cell death. On the other hand, it was proved to be free of the endocrine effects of the natural compound. The aim of this study was to find the optimal dose and administration route for in vivo tumor therapy in an animal model. We have investigated the dose--and administration route-dependent antitumor activity of TT-232 on S-180 sarcoma tumor transplanted to inbred BDF1 mice from SPF breeding. Long-term administration (i.p., s.c. and i.v. injections) was started either on the day subsequent to tumor transplantation or after the development of tumor. The antineoplastic potential of TT-232 was evaluated on the basis of survival and tumor growth inhibition. In long-term administration (injections twice a day for 2 weeks) a significant, but dose- and administration route-dependent therapeutic efficacy of TT-232 was observed. The optimum dose of TT-232 15 micrograms/kg which resulted in a 30-40% cure rate and 50-70% growth inhibition in S-180 sarcoma tumor. A moderate antitumor effect was achieved by TT-232 when it was administered after the evelopment of tumor. Our study suggests that TT-232 can be a promising antitumor agent.
Insights
The somatostatin analog TT-232 shows significant antitumor activity in mouse models, with optimal results at 15 micrograms/kg. This agent effectively inhibits tumor growth and induces cancer cell death without endocrine side effects.
Area of Science:
- Pharmacology
- Oncology
- Biochemistry
Background:
- The somatostatin analog TT-232 demonstrates in vitro and in vivo antitumor properties.
- TT-232 inhibits tyrosine kinases and induces programmed cell death.
- Unlike natural somatostatin, TT-232 lacks endocrine effects.
Purpose of the Study:
- To determine the optimal dose and administration route for TT-232 in vivo.
- To evaluate the antitumor efficacy of TT-232 in an S-180 sarcoma mouse model.
Main Methods:
- Investigated dose- and administration route-dependent antitumor activity of TT-232.
- Administered TT-232 via intraperitoneal, subcutaneous, and intravenous injections.
- Evaluated antineoplastic potential based on survival and tumor growth inhibition.
Main Results:
- Long-term TT-232 administration showed significant, dose- and route-dependent efficacy.
- The optimal dose of 15 micrograms/kg resulted in a 30-40% cure rate and 50-70% growth inhibition.
- Moderate antitumor effects were observed when TT-232 was administered after tumor development.
Conclusions:
- TT-232 is a promising antitumor agent for S-180 sarcoma.
- Optimal therapeutic efficacy requires careful selection of dose and administration route.
- Further research into TT-232 as a cancer therapeutic is warranted.